Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.7239
Abstract: Importance Trastuzumab deruxtecan (T-DXd) has shown efficacy in patients with breast cancer with ERBB2 immunohistochemistry (IHC) scores of 1+ or 2+ but not 0 as read in central pathology laboratories. The drug is currently being… read more here.
Keywords: ihc; erbb2; breast cancer; low erbb2 ... See more keywords
Defining low-HER2 cancers using RNA quantification by next generation sequencing.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e13044
Abstract: e13044 Background: The recent success of treatment with HER2-directed antibody-drug conjugate T-DXd (trastuzumab-deruxtecan) in treating low-HER2 expression breast cancer raises the possibility of similar success in other tumors that express similarly low levels of HER2.… read more here.
Keywords: cancer; low erbb2; low her2; her2 ... See more keywords